Wei Chen | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Wei Chen | Pharmacology | Best Researcher Award

Prof. Wei Chen, Fudan University, China

Prof. Wei Chen is an Associate Professor at Fudan University, specializing in neuroscience and pharmacology. He earned his Ph.D. in Pharmacy from Fudan University and completed postdoctoral research at Stanford University. His work focuses on neuroregeneration, metabolic reprogramming, and precision medicine, with numerous high-impact publications in Nature Communications, Phytomedicine, and Advanced Biology. Prof. Chen has received multiple prestigious awards, including the National Scholarship and the Excellence Award at the International Forum of Precision Medicine. His innovative contributions span both basic research and clinical applications in neuropharmacology and renal therapy.

Publication Profile

Orcid

Education

Prof. Wei Chen πŸ§ πŸ’Š is an esteemed Associate Professor at Fudan University, Shanghai, China, serving since September 2022. Prior to this, he was a Postdoctoral Scholar in Neuroscience at Stanford University, Palo Alto, USA (2019–2022), where he advanced cutting-edge research in brain science. Prof. Chen earned his Ph.D. in Pharmacy from Fudan University in 2019, following his M.D. in Pharmacy from the Second Military Medical University (2016) and Anhui Medical University (2013). With a solid foundation in pharmaceutical sciences and neuroscience, his academic journey reflects a commitment to innovation, discovery, and excellence in health research and education πŸŒπŸ“š.

Awards

Prof. Wei Chen πŸ…πŸŽ“ has been recognized with numerous prestigious awards and fellowships throughout his academic journey. In 2019, he was honored as one of the Excellent Graduates in Shanghai and received the β€œWarm Heart” Scholarship πŸ’–. He earned the esteemed National Scholarship twice, in both 2018 and 2017, acknowledging his outstanding academic performance πŸ“˜. He also received the Excellence Award at the 2017 International Academic and Industrial Forum of Precision Medicine 🧬. Earlier, he was awarded the Best Student Award in 2016 πŸ₯‡ and secured third prize in the Million College Students Science Entrepreneurship Competition in Anhui Province in 2012 πŸ’‘πŸ†.

Research Focus

Wei Chen is a prominent researcher with a diverse focus on biomedicine, molecular therapy, and gene therapy. His work primarily explores the treatment of neurodegenerative disorders, kidney injury, liver disease, and cancer. He specializes in immune modulation, particularly through interleukin-22 (IL-22), and metabolic reprogramming to treat various diseases. His research also delves into neuroprotection, cellular regeneration, and inflammatory responses, utilizing innovative approaches like gene delivery and nanoparticle therapy. His contributions aim to transform therapeutic strategies, especially in complex conditions like pancreatic cancer and neurodegeneration.

Publication Top Notes

Qingyihuaji Formula reprograms metabolism to suppress pancreatic cancer growth and progression through LINC00346-OMA1-ATF4 signaling

Notoginsenoside Fc, a novel renoprotective agent, ameliorates glomerular endothelial cells pyroptosis and mitochondrial dysfunction in diabetic nephropathy through regulating HMGCS2 pathway

Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells

The role of interleukin-22 in lung health and its therapeutic potential for COVID-19.

VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

Interleukin-22 mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury
Interleukin-22 ameliorated acetaminophen-induced kidney injury by inhibiting mitochondrial dysfunction and inflammatory responses
Gene therapy for neurodegenerative disorders: advances, insights and prospects

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology πŸ§ͺ. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) πŸ“š. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. πŸŽ“πŸ”¬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine πŸ₯. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant πŸ“–. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies πŸ”¬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) πŸ₯. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine πŸ”¬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology πŸ“š.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate πŸ“š, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers πŸ”¬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors πŸ…. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology πŸ§ πŸ’Š, medicinal chemistry βš—οΈ, and molecular neuroscience πŸ”¬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems πŸš€, enantiomeric drug behavior πŸ”„, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.

Publication Top Notes

Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers

Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif

Synthesis and Properties of a Water-Soluble Ureide Derived from GΠ°lodif and Succinic Acid

A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers

Effect of original anticonvulsant ortho-fluoro-benzonal on immune cells functional properties at chronic ethanol intoxication

The original anticonvulsant meta-Cl-benzhydrylurea (m-CL-BHM) induces of the liver monooxygenase system and stimulates the neuroimmune response in behavioral disorders of alcoholic origin

EMBRIOGENESIS OF NEURONAL ELENENTS (GLIOBLASTS AND GABAA RECEPTORS) IN THE HUMAN BRAIN NEUROIMMUNE SYSTEM UNDER PRENATAL ALCOHOL EXPOSURE

An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism